Hospital

Vincent Young, MD, PhD, shares takeaways from Peggy Lillis Foundation's 2024 National C diff Advocacy Summit.

The CEO and co-founder of the Peggy Lillis Foundation discusses highlights from the organization's 2024 National C diff Advocacy Summit.

Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.

Shawn Riser Taylor, PharmD, CPP, CDCES, discusses the challenges and process of providing health care in a rural area of Guachipilincito in Honduras.

The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.

The severity of RSV disease among adults further highlights how crucial vaccine polices and recommendations are.

The findings emphasize a need for guideline-based care delivery for patients with severe asthma, particularly for patients who are facing social disparities within health care.

Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.

A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.

Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.

Pivmecillinam (Pivya; UTILITY therapeutics Ltd) tablets were approved for female adults with uncomplicated urinary tract infection caused by Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.

The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.

Laura Gillespie, PharmD, discusses some of the financial benefits of having a pharmacist focused on antimicrobial stewardship efforts in a health system.

Exploring challenges and opportunities in developing personalized treatments for schizophrenia

The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.

Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.

Ofatumumab (Kesimpta; Novartis) demonstrated a sustained efficacy as a first-line, continuous treatment for patients recently diagnosed and treatment-naïve with relapsing multiple sclerosis.

Laura Gillespie, PharmD, discusses the impact of pharmacist-led initiatives on health care–associated C diff rates for health care systems.

Investigators found that younger age groups had significantly longer lengths of stay compared to those older than 75 years.

Investigators found that 89% of individuals with cardiovascular disease consumed more than 1500 mg of sodium daily.

Ocrelizumab (Ocrevus; Roche) is being investigated as a twice yearly 10-minute subcutaneous injection compared to the intravenous infusion formulation.

The primary endpoint of the study was clinical remission at week 52 with vedolizumab

With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.

Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.

Regardless of how this fits into workflow, pharmacists can play a significant role in counseling patients on nutrition and holistic health.

The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.

The results displayed well tolerability and safety with Abrysvo, meeting the study’s co-primary endpoint of immunogenicity and primary safety

The product is currently being investigated alongside TLX101 in the IPAX-Linz and IPAX-2 clinical trials, and have previously shown efficacy in the IPAX-1 trial.

IMPACT CKD, a modeling analysis created by AstraZeneca, includes data about chronic kidney disease across 8 countries, including the United States.